| Dimension | Grade | Score | Evidence | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | D+ | 38 | Negative earnings (-$1.04 EPS), declining revenue (-30% YoY), micro-cap illiquidity, no dividend safety net | 6–12M |
| SA Quality/Value Composite | F | 15 | No P/E (negative earnings), null forward guidance, market cap $276M, revenue contraction severe | TTM |
| Zacks Earnings Momentum | D | 28 | EPS -$1.04, null YoY growth data, no earnings date disclosed, loss-making trajectory | FY1–FY2 |
| Institutional & Smart Money Flow | C | 42 | Volume data unavailable; beta 1.03 suggests systematic risk in line with market; micro-cap constraints | Recent |
| Growth Sustainability & Moat | D | 22 | Revenue -30% YoY, no disclosed margin data, health-care diagnostics sector (OraSure: oral-fluid testing), limited visibility on competitive positioning | 1–3Y |
| Valuation & Safety (Pre-Penalty) | C | 48 | $3.97 price, $276M market cap, 52W range $2.08–$4.58 (91% rebound from low), no target consensus, debt/balance-sheet data unavailable | Current |
| Penalty Overlay | –15 | –15 | Negative earnings, revenue contraction, illiquidity (0.36M avg volume), micro-cap crowding risk, no dividend support | Ongoing |
| CONFIDENCE SCORE | C | 52 | Core metrics (price, beta, 52W range) solid; critical gaps: no earnings date, no balance-sheet detail, no institutional ownership data | Data as-of |
| Volatility & Drawdown Risk | E | 32 | Beta 1.03, but micro-cap illiquidity amplifies tail risk; 52W high $4.58 vs. low $2.08 = 120% range; negative earnings = binary event risk | 6M rolling |
| Crowding Risk Flag | HIGH | — | Sub-$300M market cap, avg volume 0.36M shares, turnaround narrative attracts retail; limited institutional depth | Real-time |
OraSure Technologies (Nasdaq: OSUR) is a micro-cap health-care diagnostics play specializing in oral-fluid and rapid-testing platforms. At $276M market cap with a 52-week rebound of +24.45% from lows, OSUR trades on recovery optionality rather than fundamental strength. Comparable micro-cap diagnostics peers (Quidel, LumiraDx spin-offs, point-of-care labs) face similar post-pandemic demand normalization and reimbursement pressure. OSUR's -30% revenue contraction and negative earnings place it in the distressed-recovery cohort rather than growth or value. Institutional ownership data is constrained; retail and crowding risk is elevated given the turnaround narrative and sub-$5 price. The absence of earnings guidance and balance-sheet transparency limits institutional confidence.
1–3 Month Outlook (Near-Term Trading): Price momentum is neutral (0% daily change as of 31 Jul 2026). The 52-week rebound (+24.45%) suggests capitulation lows may be in place, but lack of earnings clarity and volume constraints (0.36M avg) create stop-loss vulnerability. No catalyst window identified; risk of gap-down moves on negative earnings or guidance surprises remains acute. Suitable only for short-term, high-risk traders with defined exit discipline.
6–12 Month Outlook (Strategic Horizon): Restructuring or M&A probability is elevated for a sub-$300M diagnostics firm with revenue contraction and losses. Path to profitability depends on successful product-line rationalization, cost restructuring, or new-market penetration (e.g., emerging-market oral-fluid testing, corporate wellness, international). Without disclosed guidance, visibility is low. Downside risk to $2.50–$3.00 if revenue decline persists; upside to $6.00–$7.00 only if pivots prove successful. Not suitable for risk-averse portfolios.
OSUR Stock Analysis & Forecast
Is OSUR a Good Investment in 2026?
Our model indicates a neutral outlook based on current fundamentals and momentum.
OSUR Stock Forecast
Based on recent earnings trends, valuation metrics, and sector performance, OSUR shows balanced risk-reward characteristics.
Should You Buy OSUR Now?
Investors should consider market conditions, volatility, and long-term positioning before taking a position in OSUR.